Loading
Latest filing published 18 Sept 2025 for Y-mAbs Therapeutics, Inc., €93k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Joris Wilms in Y-mAbs Therapeutics, Inc. In total, 6 filings cover trades dated from 17 January 2023 to 16 September 2025.
On the market, this insider has only sold: 1 sale, €66k in total. Outside the open market, there are 3 share grants.
The newest entry dates from 18 September 2025: a transaction, in Y-mAbs Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations